NASDAQ:GH - Guardant Health Stock Price, Forecast & News

Guardant Health trades on the NASDAQ under the ticker symbol "GH."

Guardant Health Inc (NASDAQ:GH) announced its quarterly earnings results on Thursday, November, 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.39) by $0.25. The firm earned $60.85 million during the quarter, compared to analysts' expectations of $45.40 million. Guardant Health had a negative net margin of 40.99% and a negative return on equity of 11.70%. The company's revenue was up 180.4% on a year-over-year basis. During the same period in the prior year, the company posted ($1.94) EPS. View Guardant Health's Earnings History.

Guardant Health is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Guardant Health.

7 brokers have issued 12-month target prices for Guardant Health's shares. Their forecasts range from $84.00 to $135.00. On average, they expect Guardant Health's share price to reach $109.50 in the next twelve months. This suggests a possible upside of 28.8% from the stock's current price. View Analyst Price Targets for Guardant Health.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Guardant Health.

Media stories about GH stock have trended extremely negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Guardant Health earned a coverage optimism score of -5.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Guardant Health.

Guardant Health saw a decline in short interest in the month of January. As of January 31st, there was short interest totalling 3,510,000 shares, a decline of 8.1% from the January 15th total of 3,820,000 shares. Based on an average daily trading volume, of 945,900 shares, the short-interest ratio is currently 3.7 days. Approximately 7.0% of the company's shares are short sold. View Guardant Health's Current Options Chain.

Some companies that are related to Guardant Health include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), ELEKTA AB/ADR (EKTAY), Natera (NTRA), InVitae (NVTA), Veracyte (VCYT), CareDx (CDNA), RadNet (RDNT), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Personalis (PSNL), Centogene (CNTG), DermTech (DMTK), Anpac Bio-Medical Science (ANPC) and Enzo Biochem (ENZ).

Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), Alibaba Group (BABA), Twilio (TWLO), Trade Desk (TTD), Alteryx (AYX), Okta (OKTA), Paypal (PYPL), salesforce.com (CRM), Shopify (SHOP) and Micron Technology (MU).

(GH) raised $200 million in an initial public offering on Thursday, October 4th 2018. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

Guardant Health's stock is owned by a variety of of institutional and retail investors. Top institutional investors include VK Services LLC (2.85%), Jennison Associates LLC (2.83%), Alliancebernstein L.P. (1.73%), Fred Alger Management LLC (1.42%), Capital Research Global Investors (1.20%) and Franklin Resources Inc. (0.98%). Company insiders that own Guardant Health stock include Amirali Talasaz, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Michael J Wiley, Richard B Lanman, Stanley J Meresman, Timothy P Eckersley and Vision Fund (Aiv M1) Softbank. View Institutional Ownership Trends for Guardant Health.

GH stock was sold by a variety of institutional investors in the last quarter, including VK Services LLC, Jennison Associates LLC, Point72 Asset Management L.P., Cubist Systematic Strategies LLC, Hamilton Lane Advisors LLC, Nicholas Investment Partners LP, Quantbot Technologies LP and NumerixS Investment Technologies Inc. Company insiders that have sold Guardant Health company stock in the last year include Amirali Talasaz, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Michael J Wiley, Richard B Lanman, Stanley J Meresman, Timothy P Eckersley and Vision Fund (Aiv M1) Softbank. View Insider Buying and Selling for Guardant Health.

GH stock was acquired by a variety of institutional investors in the last quarter, including Fred Alger Management LLC, Alliancebernstein L.P., Thrivent Financial for Lutherans, Franklin Resources Inc., Eagle Asset Management Inc., Credit Suisse AG, Massachusetts Financial Services Co. MA and Rhenman & Partners Asset Management AB. View Insider Buying and Selling for Guardant Health.

Shares of GH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GH stock can currently be purchased for approximately $85.00.

Guardant Health has a market capitalization of $7.98 billion and generates $90.64 million in revenue each year. The company earns $-85,060,000.00 in net income (profit) each year or ($2.80) on an earnings per share basis. Guardant Health employs 454 workers across the globe.View Additional Information About Guardant Health.

The official website for Guardant Health is http://www.guardanthealth.com/.

Guardant Health's mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The company can be reached via phone at 855-698-8887.